Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Second response from Hawk on Feb. licenses
I think the argument can be made that the change from one-time payments to ongoing royalties is a "material" change as it has far reaching implications to the PTSC business. For them to NOT let us know about that IMO would be in violation of the SEC requirements. Any educated comments about my interpretation of this issue would be appreciated.
Share
New Message
Please login to post a reply